MIRIAM NNOLI 
The Gavi vaccine alliance on Wednesday announced striking a deal with Danish Drugmaker, Bavarian Nordic to secure 500,000 Mpox jabs or use in African countries facing the epidemic.
This development came after the World Health Organization (WHO) last week prequalified an Mpox vaccine, MVA-BN, for the first time, paving the way for the United Nations (UN) and other international agencies to obtain them.
Gavi said the vaccine doses, to be delivered by the end of the year, would be purchased through its First Response Fund, which was created in June to make cash rapidly available for vaccines during health emergencies.
READ ALSO
- Mpox: Cameroon Records Two Deaths, Six Cases
- Mpox Vaccine Key For Pre-exposure Prophylaxis To Prevent Infection – NPHCDA
- Mpox Outbreak Global Emergency In Africa – WHO
Gavi’s chief Sania Nishtar said in a statement. “We are committed to working with affected governments and our partners to turn these vaccines into vaccinations as quickly and effectively as possible.”
She said the aim was “to build a global vaccine stockpile”, though that would depend on Gavi securing sufficient funding for work through 2030.
Recall, WHO declared an international emergency over mpox last month, concerned by the surge in cases of the new Clade 1b strain in the DRC that spread to nearby countries.
Between January and the end of August, DRC had recorded nearly 22,000 cases and more than 700 deaths linked to the virus.
By late August, Clade 1b had also been detected in the DRC’s eastern neighbours Burundi, Rwanda and Uganda, plus Kenya, according to the Africa Centres for Disease Control and Prevention, while single case have been detected in Sweden and Thailand.
